SANG CHARLES 4
4 · Adaptive Biotechnologies Corp · Filed Dec 11, 2020
Insider Transaction Report
Form 4
SANG CHARLES
Sr VP, Clinical Diagnostics
Transactions
- Exercise/Conversion
Common Stock
2020-12-11$6.55/sh+50,000$327,500→ 50,000 total - Sale
Common Stock
2020-12-11$56.13/sh−50,000$2,806,500→ 0 total - Exercise/Conversion
Stock Option (Right to Buy)
2020-12-11−50,000→ 155,000 totalExercise: $6.55Exp: 2028-02-07→ Common Stock (50,000 underlying)
Footnotes (2)
- [F1]The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $55.98 to 56.60, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
- [F2]The options vested with respect to 1/4 of such shares on November 1, 2018, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.